Discontinued — last reported Q4 '20
Idexx Laboratories Other long-term liabilities decreased by 6.1% to $39.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 57.5%, from $25.07M to $39.50M. Over 5 years (FY 2020 to FY 2025), Other long-term liabilities shows an upward trend with a 10.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase may indicate new long-term strategic commitments or reserves, while a decrease suggests the resolution of such obligations.
This represents miscellaneous long-term obligations that are not classified under specific debt or pension categories. T...
Varies significantly by industry; common in capital-intensive or highly regulated sectors.
other_other_accrued_liabilities_noncurrent| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $26.91M | $14.27M | $14.48M | $14.59M | $19.25M | $20.10M | $18.45M | $19.31M | $21.58M | $19.31M | $25.88M | $26.24M | $24.71M | $32.38M | $23.44M | $25.07M | $42.68M | $42.84M | $42.08M | $39.50M |
| QoQ Change | — | -47.0% | +1.5% | +0.8% | +32.0% | +4.4% | -8.2% | +4.7% | +11.8% | -10.5% | +34.1% | +1.4% | -5.8% | +31.0% | -27.6% | +6.9% | +70.2% | +0.4% | -1.8% | -6.1% |
| YoY Change | — | — | — | — | -28.5% | +40.9% | +27.4% | +32.4% | +12.1% | -3.9% | +40.3% | +35.9% | +14.5% | +67.7% | -9.4% | -4.4% | +72.7% | +32.3% | +79.5% | +57.5% |